Overview
- Third-quarter revenue reached $15.19 billion, up 12% year over year, with adjusted EPADS of $1.19, topping forecasts.
- Oncology revenue rose 19% to $6.64 billion, representing 44% of total sales.
- Key medicines advanced: Tagrisso up 11% to $1.86 billion, Imfinzi up 33% to $1.60 billion, Calquence up 13%, Lynparza up 7%, Enhertu up 40%, and Farxiga up 10% to $2.14 billion.
- U.S. sales climbed 9% to $6.55 billion, and Reuters reported the company is leaning on U.S. expansion and the pricing deal to counter import-tariff pressures.
- AstraZeneca reaffirmed guidance for high single-digit revenue growth and low double-digit core EPS growth for 2025, and shares rose about 3% intraday.